Compare DexCom, Inc. (DXCM) vs T1 Energy Inc. Common Stock (TE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs T1 Energy Inc. Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while T1 Energy Inc. Common Stock trades at $2.74 (market cap $946.42M). The key difference: DexCom, Inc. is far larger — about 33.9× T1 Energy Inc. Common Stock's market cap, and DexCom, Inc. is trading nearer its 52-week high, T1 Energy Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| DXCM | TE | |
|---|---|---|
Market Cap | $32.09B | $946.42M |
Volume | 3,819,730 | 12,898,774 |
Sector | Health | Industrials |
52-Week High | $92.34 | $12.04 |
52-Week Low | $54.84 | $2.72 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $1.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About T1 Energy Inc. Common Stock
T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →
